AMSilk will use $61m funding to meet growing silk-based biotech demand

Core Insights - AMSilk's recent funding reflects strong investor confidence and a commitment to its technology and market potential [1] - The financing, led by ATHOS, includes €30 million in equity and €22 million in convertible bonds, aimed at supporting AMSilk's industrial scale-up [1] - AMSilk aims to meet the growing global demand for silk-based protein materials [2] Investment and Financial Strategy - The investment demonstrates confidence in AMSilk's scalable technology and strong partner network, crucial for industrial-scale production [3] - AMSilk has established multi-year production agreements to ensure long-term industrial output and supply reliability [3] Production Capabilities - AMSilk has installed dedicated production facilities for manufacturing silk-based protein materials, ensuring consistent quality and reliability [4] - The company’s technology reprograms microorganisms to produce biodegradable, microplastic-free biomaterials, which can be processed into various forms [5] Market Applications - The silk-based biomaterials are utilized in textile applications for the fashion and automotive industries, as well as functional ingredients in the consumer care sector [5]